IVAX Agreement With Rival BMS Appears To Buttress BMS control of Paclitaxel
FY2000 Appropriations: NIH Gets $17.9 Billion, A 15% Increase, In Final Budget Agreement; $3 billion to Be Delayed
Letter to the Editor: A Victory for Research, But Real Work Is Ahead
Commentary: NCI’s Budge Proposal ForFY2001 Offers A Blueprint for Research
Science Policy: Second-Hand Smoke Linked To Lung Cancer, Other Health Effects
Funding Opportunities: RFA Available: Teams For Molecular Target Assessment
In Brief: Paul Van Nevel, Director Of NCI Communications, To Retire At Year’s End
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - CBER Director Vinay Prasad dared to “say no to drugs”
- J. Craig Venter’s work was foundational to cancer advancement of the past 25 years
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)









